Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children
Schnadower D, Tarr PI, Casper TC, Gorelick MH, Dean JM, O'Connell KJ
Published in New England Journal of Medicine
Methodology
Randomized, double-blind, placebo-controlled trial of 5 days of L. rhamnosus GG in children aged 3-48 months with acute gastroenteritis across 10 US emergency departments
Key Findings
Moderate-to-severe gastroenteritis within 14 days occurred in 11.8% of the LGG group vs 12.6% of placebo (RR 0.96, 95% CI 0.68-1.35); no differences in diarrhoea duration, vomiting or missed daycare.
Conclusions
L. rhamnosus GG did not improve outcomes in preschool children with acute gastroenteritis.
Limitations
Restricted to acute paediatric gastroenteritis; does not address preventive or adult indications.
Supplements Studied
Among preschool children with acute gastroenteritis, those who received a 5-day course of L. rhamnosus GG did not have better outcomes than those who received placebo.
Among preschool children with acute gastroenteritis, L. rhamnosus GG did not prevent development of moderate-to-severe gastroenteritis within 14 days.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
NIH (NICHD, NCATS)
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.